News

GeneType Clinicians’ Adoption Growing – Sales up 5-Fold Year on Year

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader…

2 years ago

Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

WILMETTE, Ill., April 16, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing…

2 years ago

Vittoria Biotherapeutics Announces Keith Westby as Chief Operating Officer

PHILADELPHIA, April 16, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics, a clinical-stage cell therapy company, has announced that Keith Westby has…

2 years ago

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

The first patient was dosed in the Phase 1 dose escalation trial of CTX-8371.This study is conducted in patients with…

2 years ago

Certara Launches Cloud Platform to Further Unify its End-to-End Scientific Software Platform

PRINCETON, N.J., April 16, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today…

2 years ago

FountainRx Selects Inovalon’s ScriptMed® Software To Enhance Patient Care and Scale Specialty and Infusion Pharmacy Services

ScriptMed Cloud-Based SaaS Software Enables Data-Driven Workflows and Provides More Personalized, Cost-Effective Care for Patients with Complex Health ConditionsBOWIE, Md.,…

2 years ago

Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis

Nes-Ziona, Israel, April 16, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

2 years ago

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE)…

2 years ago

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated…

2 years ago

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024

CANTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on…

2 years ago